Haematological side effects of clozapine: Patient characteristics

New Zealand Medical Journal

Volumn 110, Issue 1041, 1997, Pages 125-127

  Miller, P R ^a   Cutten, A E C ^b  

^a Hillmorton Hospital   (New Zealand)

^b Sandoz Pharma Ltd   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEW ZEALAND; PREVALENCE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG MONITORING; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPENIA; NEW ZEALAND; PREVALENCE; SCHIZOPHRENIA;

EID: 0030892325     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Baidessarini RJ. Chemotherapy in psychiatry: principles and practice. Cambridge, Mass.: Harvard University Press, 1985; 14-92.
2. Hunziker F, Kunzle F, Schmutz J. Uber ein 5-Stellung basisch substituierte 5H-Dibenzo (b.e.) -1,4-diazepine. Helv Chim Acta 1963; 46: 2337-46.
3. Gross H, Langner E. Das Wirkungsprofil eines chemisch neuartigen Breitbendneuroleptikums der Dibenzodiazepingruppe. Wem Med Wochenschr 1966, 116: 814-6.
4. Angst J, Jaenicke U, Padrutt A, Scharfetter C. Ergbenisseeines Doppelblindversuches von HF 1854 (8-chlor-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e) (1,4)diazepin) im Vergleich zu Levomepromarin. Pharmakopsychiatrie 1971b; 4: 192-200.
5. Hippius H, Kanig J. Die Agranulocytose unter neuropsychiatrischer Phenothiazin-Therpaie. Artzl Wochenschr 1958: 501-7.
6. Amsler HA, Teerenhove L, Barth E, et al, Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand 1977; 56: 241-8.
7. Andermann B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharm 1977; 11: 199-201.
8. Jose MaJA, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis - incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-7.
9. Kane J, Honigfield G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenia. Arch Gen Psychiatry 1988; 45: 789-96.
10. Carpenter WT. The deficit syndrome (editorial). Am J Psychiatry 1994; 151: 3.
11. Hawkins T, Carter JM, Romeril KR, Jackson SR, Green GJ. Severe trimethoprim-induced neutropenia and thrombocytopenia. NZ Med J 1993; 106: 251-2.
12. Wolk SI, Douglas CJ. Clozapine treatment of psychosis in Parkinson's Disease: A report of five consecutive cases. J Clin Psychiatry 1992; 53: 10.
13. Clozaril Newsletter - Clozaril Patient Monitoring Service, Sandoz, UK, 1995 (Spring); No 11.
14. Lieberman JA, Johns CA, Jane JM, et al. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 1988; 49: 271-7.
15. Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Lieberman JA. Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis. J Lab Clin Med 1992; 119: 254-66.
16. Gerson SL, Arce C, Meltzer HY. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994; 86: 555-61.
17. Safferman AZ, Lieberman JA, Jose MaJA, Howard A. Rechallenge in clozapine-induced agranulocytosis. Lancet 1992; 339; 1296-7.
18. Banhov MD, Tohen M, Friedberg J. High risk of eosinophilia in females treated with clozapine. J Clin Psych 1993; 54: 466-9.
19. Tiihonen J, Paanila J. Eosinophilia associated with clozapine (letter). Lancet 1992; 339: 488.
20. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hospital Community Psychiatry 1994; 45: 261-4.